Scott Donaldson
University of North Carolina at Chapel Hill
H-index: 43
North America-United States
Top articles of Scott Donaldson
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC … | Journal of Cystic Fibrosis | Scott H Donaldson Timothy E Corcoran Joseph M Pilewski Beth L Laube Peter Mogayzel | 2024/2/13 |
Effect of second booster vaccinations and prior infection against SARS-CoV-2 in the UK SIREN healthcare worker cohort | The Lancet Regional Health–Europe | Peter D Kirwan Victoria J Hall Sarah Foulkes Ashley D Otter Katie Munro | 2024/1/1 |
Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis | Journal of Cystic Fibrosis | Scott H Donaldson Timothy E Corcoran Joseph M Pilewski Peter Mogayzel Beth L Laube | 2024/1/1 |
Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis | Heliyon | Kadambari Vijaykumar Hui Min Leung Amilcar Barrios Justin Wade Heather Y Hathorne | 2024/4/16 |
P094 A Phase II study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 in patients with cystic fibrosis bronchiectasis (the Clairafly … | Journal of Cystic Fibrosis | MA Mall W Sauter JC Davies S Donaldson A Eleftheraki | 2023/6/1 |
586 Cardiovascular risk factors in cystic fibrosis: screening and management practices of cystic fibrosis providers | Journal of Cystic Fibrosis | K Despotes A Ceppe S Donaldson J Goralski | 2023/10/1 |
Mucolytics for Near-Fatal Asthma | EC Thompson SH Donaldson MO Al-Qadi | 2023/5 | |
113 Effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in people with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: The … | Journal of Cystic Fibrosis | S Donaldson T Corcoran J Pilewski B Laube P Mogayzel | 2023/10/1 |
RANDOMIZED, OPEN-LABEL NON-INFERIORITY TRIALS EVALUATING DISCONTINUATION VERSUS CONTINUATION OF HYPERTONIC SALINE OR DORNASE ALFA IN MODULATOR TREATED PEOPLE WITH CYSTIC … | The Lancet. Respiratory medicine | Nicole Mayer-Hamblett Felix Ratjen Renee Russell Scott H Donaldson Kristin A Riekert | 2023/4 |
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective | Nicole Mayer-Hamblett John Paul Clancy Raksha Jain Scott H Donaldson Isabelle Fajac | 2023/10/1 | |
Alterations in lipids after initiation of highly effective modulators in people with cystic fibrosis | Journal of Cystic Fibrosis | Katherine A Despotes Agathe S Ceppe Scott H Donaldson | 2023/11/1 |
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre … | The Lancet Respiratory Medicine | Nicole Mayer-Hamblett Felix Ratjen Renee Russell Scott H Donaldson Kristin A Riekert | 2023/4/1 |
More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice | Scott H Donaldson | 2023/7/1 | |
119 Interim results of test reliability of 19F MRI in mild cystic fibrosis lung disease | Journal of Cystic Fibrosis | J Goralski S Chung M Powell A Ceppe Y Lee | 2023/10/1 |
Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI | Journal of Cystic Fibrosis | Sarah Jane Schwarzenberg Phuong T Vu Michelle Skalland Lucas R Hoffman Christopher Pope | 2023/3/1 |
Feasibility of free‐breathing 19F MRI image acquisition to characterize ventilation defects in CF and healthy volunteers at wash‐in | Magnetic Resonance in Medicine | Sang Hun Chung Khoi Minh Huynh Jennifer L Goralski Yong Chen Pew‐Thian Yap | 2023/7 |
639 Improving care for cystic fibrosis adults with advanced lung disease | Journal of Cystic Fibrosis | L Gifford N Bingham N Efland D Enloe J Goralski | 2023/10/1 |
Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial | American journal of respiratory and critical care medicine | David P Nichols Alex C Paynter Sonya L Heltshe Scott H Donaldson Carla A Frederick | 2022/3/1 |
DEPRESSION AND ANXIETY SYMPTOMS FOLLOWING ELEXACAFTOR/TEZACAFTOR/IVACAFTOR IN ADULTS WITH CYSTIC FIBROSIS | Jennifer Goralski Harish Pudukodu A Ceppe S Donaldson NA Sowa | 2022/12/23 | |
46 Lipid trends on highly effective modulators in cystic fibrosis | Journal of Cystic Fibrosis | K Despotes A Ceppe S Donaldson | 2022/10/1 |
